Soothing Morning Sickness

medmalaa Medical News You Can Use Leave a comment

Posted by: Cami McEvers

Morning sickness can plague a mother-to-be all day, preventing her from getting the nutrition she and her baby need.

The American College of Obstetricians and Gynecologists offers these suggestions to help soothe morning sickness:

  • Make sure you get enough rest.
  • Stay away from odors that upset your stomach.
  • Instead of eating three large meals each day, eat five to six smaller meals throughout the day.
  • Before getting out of bed, eat a few crackers to calm your stomach.
  • Snack on protein-rich foods, such as yogurt.
  • Skip foods that are greasy or high in fat.

 

Source: http://www.nlm.nih.gov/medlineplus/news/fullstory_132666.html

AAP Releases New C. Diff Guidance

medmalaa Medical News You Can Use Leave a comment

Posted by: Cami McEvers

Even when infants have a positive test for Clostridium difficile, clinicians should search for other causes of disease, according to a policy statement from the American Academy of Pediatrics (AAP).

That’s because children younger than 12 months have high rates of colonization with the bacteria (37% before 1 month, 30% from 1 to 6 months, and 14% from 6 to 12 months), the authors noted in the statement published online ahead of the January issue of Pediatrics.

For children ages 1 to 2 years, a positive C. difficile test indicates possible infection, although other causes of disease should be sought, according to the recommendations.

For those ages 3 and older  –  who have rates of colonization similar to those seen in nonhospitalized adults (0% to 3%)  –  a positive test reflects probable infection. Factors that have been associated with a greater risk of C. difficile in these older children include antimicrobial therapy, use of proton pump inhibitors, underlying bowel disease, renal insufficiency, and impaired humoral immunity, the authors wrote.

As in adults, endoscopic or histologic test results positive for pseudomembranous colitis are indicative of definite infection with C. difficile in children.

The AAP released the recommendations to update information about C. difficile infections in a pediatric population for two reasons: Infections have been increasing among hospitalized children in the U.S. in recent years, possibly related to the emergence of North American pulsed field type 1 (NAP1), the epidemic strain of toxin-producing C. difficile. Also, recent guidelines for management in adults do not necessarily reflect issues specific to infections in children.

The authors addressed diagnostic testing for C. difficile in children, noting that “it is prudent to avoid routine testing … in children younger than 1 year” because of the high rates of carriage.

However, breastfed infants have lower carriage rates (14%) compared with formula-fed infants (30%).

“Testing for C. difficile can be considered in children 1 to 3 years of age with diarrhea, but testing for other causes of diarrhea, particularly viral, is recommended first,” they wrote. “For children older than 3 years, testing can be performed in the same manner as for older children and adults.”

Among other recommendations for testing:

  • Testing for C. difficile colonization or toxins should only be performed when clinical and age conditions are met.
  • In infants, testing should be limited to those with Hirschsprung disease or other severe motility disorders or during an outbreak.

 

With regard to treatment, the guidelines state that following treatment, a test of cure is not recommended because the bacteria, its toxins, and genome are shed for weeks after diarrhea is resolved. Testing for recurrences less than 4 weeks after initial testing is only useful when the results of repeat testing are negative.

Also, discontinuing antimicrobial agents is the first step for treatment and might be sufficient for resolving the infection. Anti-peristaltic medications should not be used because they can obscure symptoms and cause complications.

For moderate disease, the drug of choice for a first episode or first recurrence is metronidazole given orally (30 mg/kg/day) in four divided doses (maximum of 2 g/day).

Finally, for severe disease or a second recurrence, clinicians should use oral vancomycin (40 mg/kg/day) given in four divided doses (maximum of 2 g/day), with or without metronidazole.

The statement also dealt with infection control, calling on healthcare professionals to use gloves with symptomatic patients to prevent patient-to-patient spread; wash their hands with soap and water, which is more effective for removing the spores than using an alcohol-based hand sanitizer; and use chlorine products for environmental cleaning.

 

Source: http://www.medpagetoday.com/InfectiousDisease/GeneralInfectiousDisease/36655?

Michigan hospital blazes trail in fight against fungal meningitis

medmalaa Fungal Meningitis Leave a comment

Posted by: Cami McEvers

Bonita Robbins (L ), a patient suffering with arachnoiditis due to a contaminated steroid injection, sits on her hospital bed as she and her husband Ed (C ) listen to Infectious Diseases doctor Anurag Malani at St. Joseph Mercy Ann Arbor hospital in Ypsilanti, Michigan December 21, 2012. St. Joseph Mercy — a 537-bed Catholic hospital located on the doorstep of the University of Michigan — has played an outsized role in the fight against one of the largest fungal meningitis outbreaks in US history, treating 169 of the state's 223 cases, including 7 people who died.

After his first day working at St Joseph Mercy Ann Arbor hospital’s newly created Fungal Outbreak Clinic, Dr David Vandenberg struggled to describe to his boss the enormity of what lay ahead. He settled on a line from the movie Jaws.

“We’re going to need a bigger boat,” Vandenberg told Dr Lakshmi Halasyamani, chief medical officer of the Michigan hospital, echoing the film’s local police chief after he first eyes a 25-foot (7.5-metre) killer shark.

The St Joseph Mercy clinic has been at the front line of the fight against one of the biggest ever U.S. outbreaks of fungal meningitis, a killer infection that has been traced to tainted steroid shots from a Massachusetts pharmacy.

So far, 620 Americans have developed serious infections related to the outbreak, including 367 cases of deadly meningitis, and 39 people have died. Of the 19 U.S. states affected, Michigan has been worst hit, handling more than one third of the total cases in the outbreak.

St Joseph Mercy – a 537-bed Catholic hospital located in Ypsilanti, on the doorstep of the University of Michigan – has treated 169 of the state’s 223 cases of infections that can cause meningitis, including 7 people who died.

At one point it was so overrun that 87 of its 537 beds, which are usually occupied by patients with cancer or heart ailments and the like, were occupied by patients with fungal meningitis and related infections.

Dr Tom Chiller, the fungal disease expert at the U.S. Centers for Disease Control and Prevention, who has been overseeing the outbreak, praised the work of the hospital in helping to limit deaths from the outbreak.

“They have been incredibly creative in dealing with these complicated patients,” he said.

In all, almost 14,000 people seeking relief from back and joint pain received injections from moldy steroid shots made at the now-bankrupt New England Compounding Center in Massachusetts before they were recalled in late September.

CDC experts initially feared death rates in the 40 to 50 percent range; instead, only about 6 percent of those infected have died, and the CDC credits the creative and dogged efforts of state and local health officials for keeping the death rates so low.

The first wave of the outbreak involved the most severe cases of meningitis – an inflammation of the membranes that cover the brain and spinal cord. But starting in mid-October, patients who had been recovering from meningitis were developing potentially fatal localized infections near the site where contaminated drug was injected to treat back or neck pain.

As they started seeing more cases of these local, secondary infections, the staff at St Joseph’s devised a bold plan to screen all patients in their database looking for potential new infections that might have been missed in the first wave.

On December 20, the CDC issued an alert to doctors incorporating some of lessons learned by the efforts of doctors at St Joseph’s and other hospitals, calling for increased screening of patients who may be harboring localized infections.

 

Bonita Robbins (L ), a patient suffering with arachnoiditis due to a contaminated steroid injection, sits on her hospital bed as she talks with Infectious Diseases doctor Anurag Malani at St. Joseph Mercy Ann Arbor hospital in Ypsilanti, Michigan December 21, 2012.

 

A BEWILDERING FUNGI

Among the patients who developed secondary infections was Bonita Robbins, a 72-year-old retired nurse from Pinckney, Michigan, who received doses of the tainted drug at the Michigan Pain Specialists clinic in the nearby town of Brighton while seeking relief for lower-back pain.

The first shot brought some relief, the second did little to ease her aches, and the third was contaminated. In October, Robbins went to St Joseph’s with a severe headache, back pain and pain in her thighs.

 

She spent 37 days in the hospital taking two kinds of antifungal drugs.

Dr Anurag Malani, an infectious disease specialist treating Robbins, said the challenge with the outbreak was that there was no medical literature to fall back on.

“No one has ever seen anything of this magnitude related to fungal infections, ever,” he said.

Chiller said U.S. doctors had never treated meningitis caused by Exserohilum rostratum, the environmental mold causing most of the infections.

“It’s just a rare, rare cause of infection.” Seeing that mold in the meninges – membranes covering the brain and spinal cord – is “completely new.”

Initially, St Joseph’s Fungal Outbreak Clinic was started in order to coordinate the care of patients after their discharge, which included overseeing the administration of a complex regime of anti-fungal drugs.

It morphed into something bigger when some of its 53 patients with meningitis started returning with infections near the site in their back or neck where the contaminated drug was injected.

A sign is seen outside the door to the Fungal Outbreak Clinic at St. Joseph Mercy Ann Arbor hospital in Ypsilanti, Michigan December 21, 2012.

 

GETTING THE ‘BIGGER BOAT’

“When it became obvious that the number of patients would be a much higher percentage than anticipated by the CDC, we expanded our clinic and started enlisting the help of several other hospitals,” Vandenberg said.

Many of the patients had spinal abscesses, an infection in the space between the outside covering of the spinal cord and the bones of the spine. Others developed arachnoiditis, an infection of nerves within the spinal canal.

The decision to screen all patients in the hospital database who might have received tainted injections was not taken at the recommendation of the CDC.

“That was our own decision,” said Vandenberg, a specialist in internal medicine overseeing the screening effort.

He admitted that the strategy was aggressive, but said that, especially early on, doctors feared the local infections might be precursors to meningitis, making catching them early a potentially life-saving move.

Excluding patients who had already been screened and those who had injections in areas other than the spine, the hospital targeted about 500 patients for MRI scans.

Most so far have had private insurance that covers the screening. For the uninsured, the hospital’s Patient Financial Services department has been helping them to apply for financial support.

“We did over 400 MRIs in about a 4-week period,” Vandenberg said. The hospital screened so many patients, in fact, that the state of Michigan sent in an emergency mobile MRI unit to help.

Vandenberg got the task of reading stacks of MRI reports, sometimes as many as 30 a day.

So far, about 20 percent of the MRIs have shown up as abnormal, meaning that patients have to come back for surgery and treatment.

Vandenberg makes all of those calls personally. Not all of them go smoothly. He likens the gravity of the conversation – learning you have a potentially deadly new disease that requires months of treatment with risky drugs – to telling someone they have cancer.

After one especially tough call, in which a heart patient feared he would not survive the surgery he would need to clear his infection, Vandenberg cracked.

“I started crying. I probably haven’t cried for 15 years.”

Dr. David Vandenberg shows a digital slide of a patients MRI showing the infected area of the spine, due to a contaminated steroid infection, at the Fungal Outbreak Clinic at St. Joseph Mercy Ann Arbor hospital in Ypsilanti, Michigan December 21, 2012. St.

SIGNS OUTBREAK IS EASING

But at last, after months of onslaught, there are signs the outbreak is easing.

Attendance at the hospital’s daily support group has begun to taper off. And since the beginning of December, more than 50 patients with fungal infections have been discharged, while only 20 have been admitted, bringing the total number of fungus-related inpatient to 30.

Vandenberg nevertheless cautions that the outbreak is still far from over.

“Every single day of this screening program, we’re finding one or two cases that are abnormal and need to be admitted,” he said.

Vandenberg gave the CDC access to the clinic’s database so the agency could see how the effort turned out, and this month, the CDC issued the alert to doctors incorporating some of the results of the MRI screening program.

The alert warned that some patients who got tainted injections but did not develop meningitis may still be at risk of localized infections.

And it urged doctors to consider ordering an MRI for all patients who still have pain, even if the pain is similar to what sent them in for treatment in the first place.

Chiller said the United States had not yet reached the end of the outbreak.

“Unfortunately, with fungi, the incubation periods are so long and they can remain indolent. I’m definitely concerned that we’re going to continue to see more cases.”

Source: http://www.reuters.com/article/2012/12/30/us-usa-meningitis-michigan-idUSBRE8BT03X20121230

Thousands of U.S. Babies Born With Cleft Lip, Palate Each Year

medmalaa Medical News You Can Use Leave a comment

Posted by: Cami McEvers

HealthDay news image

But most of the time surgery can correct the defect, experts say

MONDAY, Dec. 31  (HealthDay News) — When Americans hear “cleft lip” or “cleft palate,” they often think of children in developing countries, but U.S. babies are by no means immune to the birth defect.

Each year about 7,000 American children are born with an oral cleft defect, according to the U.S. Centers for Disease Control and Prevention. This means that their lip hasn’t formed completely and isn’t closed properly in the case of cleft lip or, in the case of cleft palate, that there’s a hole in the roof of their mouth.

The good news, though, is that the condition is treatable.

“The outcomes for children are excellent,” said Dr. Joseph Shin, chief of the division of plastic and reconstructive surgery at Montefiore Medical Center in New York City. “Children do fine with it. It’s not the end of the world.” Shin has served on humanitarian surgical missions for Operation Smile and other organizations to repair cleft lips and cleft palates in countries in South America, Mexico, Morocco and the Middle East.

Cleft lip and cleft palate aren’t just cosmetic concerns, however. “There’s a lot of function in the palate and the lip,” explained Dr. Laura Swibel Rosenthal, an assistant professor in the departments of otolaryngology and pediatrics at Loyola University’s Stritch School of Medicine in Chicago. “Babies have to eat and not have food go up through their nose.”

Children born with these conditions can also have problems with their ears and sinuses because fluids can travel where they shouldn’t. If the defects are not corrected when children are young, they can also interfere with a child’s ability to speak properly. And, when the cleft is in the front of the mouth, it interferes with the development of the teeth, said Swibel Rosenthal, who added that sometimes, surgery is needed to move the jaw forward.

It’s not clear exactly what causes oral clefts, according to the March of Dimes. Some factors that have been associated with an increased risk for cleft lip and palate include changes in some genes, a deficiency of folic acid before pregnancy, taking certain medications while pregnant, drinking alcohol during pregnancy and having certain infections during pregnancy.

But the biggest risk factor linked to oral clefts is smoking during pregnancy. About one in five babies born with a cleft lip or palate is born to a mother who smoked, according to the March of Dimes.

Shin noted, however, that “sometimes you can do everything right, and you can still have a child with cleft lip or palate.”

For babies born with a cleft lip or palate, surgery is the main treatment. For cleft lip, he said, surgery is generally scheduled when the child is about 3 months old. For a cleft palate, surgery is usually done at about 1 year old or slightly younger so that there are fewer issues with speech, he said.

“The sooner you can do the repair, the better babies heal,” Shin said.

Besides the procedures to repair the cleft lip or palate, children often also need surgeries for ear tubes to keep their ears clear of fluids while the repair is healing.  Depending on the severity of the cleft palate and how the initial surgery has healed, children sometimes need a second surgery on their palates when they’re 3 to 7 years old, according to Swibel Rosenthal. Also, cleft lips sometimes require a second surgery to get a better cosmetic outcome, she said. Most kids also will need braces, she added.

“Parents shouldn’t be nervous about these conditions,” Swibel Rosenthal said. “Although they sometimes require multiple surgeries, there are ways to treat cleft lip and cleft palate that are simple, and children do very well.”

Because cleft lip and palate can be genetic conditions, it’s possible that subsequent pregnancies may result in another baby being born with cleft lip or palate, though the odds are relatively low, she said. “If there’s only one family member affected, the chances of another child having an oral cleft are about 4 percent,” she noted. “If two or more family members are affected, the chances of another child having it are about 9 percent.”

SOURCES: Joseph H. Shin, M.D., chief, division of plastic and reconstructive surgery, Montefiore Medical Center, New York City; Laura Swibel Rosenthal, assistant professor, departments of otolaryngology and pediatrics, Stritch School of Medicine, Loyola University, Chicago at www.nlm.nih.gov/medlineplus/news/fullstory_132667.html 

D.C. Week: FDA on Defense Over Meningitis Outbreak

medmalaa Fungal Meningitis Leave a comment

Posted by: Cami McEvers

Published: November 17, 2012

WASHINGTON  –  Calls from FDA Commissioner Margaret Hamburg, MD, for greater clarity in her agency’s oversight of compounding pharmacies were met with mixed reviews this week on Capitol Hill.

Lawmakers Question FDA Over Meningitis Outbreak

Senators from both political parties said Thursday they plan to craft legislation to give the FDA authority over compounding pharmacies the agency says is needed in light of the ongoing fungal meningitis outbreak that has killed 32 people.

“Hopefully, we’ll have something soon next year to help put this sad chapter behind us,” Senate Health, Education, Labor, and Pensions Committee Chair Tom Harkin (D-Iowa) said at the close of a Senate hearing examining the meningitis outbreak.

But Republicans in the House chastised Hamburg on Wednesday and told her they believe the FDA may already have all the authority it needs to have prevented the current outbreak. Federal drug regulators just were too slow to act after nearly a decade or warnings about the New England Compounding Center, they suggested.

 

Source: http://www.medpagetoday.com/Washington-Watch/Washington-Watch/35996

Meningitis Outbreak Still a Challenge

medmalaa Fungal Meningitis Leave a comment

Posted by: Cami McEvers

As part of the Year in Review series, MedPage Today reporters are revisiting major news stories and following up with an analysis of the impact of the original report, as well as subsequent news on the topic. Here’s what’s happened with the fungal meningitis outbreak since we published our first report.

The fungal meningitis outbreak that made headlines in the fall was “unprecedented,” in the words of the of the clinicians at the eye of the storm.

What’s more, “we’re not out of the woods yet,” said Tom Chiller, MD, deputy director of the CDC’s mycotic diseases branch.

The outbreak was unprecedented for its size, for the spectrum of disease, for the clinical challenges that faced doctors, and for the way the pattern of illness has changed since the outbreak began, Chiller told MedPage Today.

It also has enormous implications for patients, their families, hospitals, and insurers, said Carol Kauffman, MD, a fungal infections expert at the University of Michigan in Ann Arbor, Mich.

“The extent and repercussions of this outbreak, in comparison to other smaller outbreaks, are really amazing,” Kauffman told MedPage Today. “The huge morbidity and, for some, mortality, is enormous.”

The outbreak, which has been linked to an injectable drug widely used to control chronic pain, has also seen the FDA under attack for not doing more to monitor so-called “compounding pharmacies.”

And the FDA has responded by saying it did not have clear authority to intervene, even though worries about the pharmacy in question, the New England Compounding Center (NECC) of Framingham, Mass., date back to at least 2002.

The agency is now asking for its authority to be clarified, although an organization representing compounding pharmacies has told lawmakers the FDA had all the power it needed, but just dropped the ball.

The bottom line from a public health standpoint is that as of Dec. 17, the CDC had recorded 620 cases of disease and 39 deaths. And more are likely, according to Chiller: “We’re still in the middle of this thing.”

Compounding Out of Bounds

The outbreak can be said to have started in the summer, when NECC made 17,675 vials of preservative-free methylprednisolone acetate, an injectable steroid, and shipped them to 76 healthcare facilities in 23 states.

That was problematic in itself: The company was licensed as a compounding pharmacy, meaning in principle it was allowed only to make up small quantities of specialized drugs, after getting a prescription from a doctor for an individual patient.

Instead, it was acting more like a large-scale drug manufacturer, and had been for some years, according to Massachusetts officials, which should have placed it under the FDA’s authority.

The manufacturing scale played a key role in what ensued: more than 13,000 people were exposed to the drug when they got injections – mainly into the spine – to control chronic pain.

They were also exposed to a fungal contaminant in the steroid vials, later found to be a black mold called Exserohilum rostratum, which only rarely causes human disease.

Oddly, the index case for the outbreak, reported to health authorities on Sept. 18, was a 56-year-old man in Nashville who had a case of meningitis apparently associated with the fungus Aspergillus fumigatus.

It is so far the only case in the outbreak in which A. fumigatus has been found, although a pathogen has not been definitively identified in all cases, largely because fungi are very hard to grow. And it has not been found in any of the unopened vials of the steroid.

Clinical Picture of the Outbreak

For the most part, the earliest cases presented with very severe symptoms, including stroke, Chiller said, and clinicians were initially grappling in the dark.

“When we started, early in the outbreak, we had some very sick people that died of strokes, some of which happened fast before we even knew what was going on,” he said.

But almost immediately the clinical picture of the outbreak began to change, largely because of the public health efforts of the CDC and state health authorities.

As events unfolded, details of the NECC customer list allowed health authorities to call thousands of pain patients and get them to hospitals for testing.

One effect of that, Chiller said, is that clinicians saw that unprecedented spectrum of disease – from the deadly symptoms seen commonly in the early days to milder illness that was only picked up because patients were called in for a spinal tap.

Would those patients with mild disease have gone on to become even more ill? No one really knows, but Chiller and his colleagues think they probably saved some lives.

A physician who was involved in combating a similar outbreak in 2002 credits the CDC with an impressive response to what he called a “national disaster.”

“I suspect there is nowhere in the world that an agency could respond so efficiently, rapidly, and accurately,” commented John Perfect, MD, of Duke University in Durham, N.C.

Indeed, if there is good news about the outbreak, it’s the CDC’s role, according to Kauffman.

The event “highlights the ability of the CDC to respond quickly in tracking this outbreak and providing timely updates and recommendations for treatment to clinicians,” Kauffman said.

A Clinical Conundrum

The outbreak had clinical puzzles from the beginning. Why did some patients show up with serious cerebrospinal illness, but no focal infection where they got the steroid shot?

Equally puzzling, why did some patients, initially treated for meningitis, later develop a focal infection at the injection site?

And why has there been a third wave of disease in which patients only have the focal infection?

For those latter patients, Chiller noted, “the challenge is just identifying them.” While they had pain at the injection site, he said, it was hard for patients to tell whether the pain was any worse than the baseline pain that initially led them have the steroid injection.

In the absence of the continuing public health effort, they might not have sought treatment. Whether they would then have developed more serious illness remains uncertain.

There was also the question of treatment, which was developed on the fly in the first few days and weeks of the outbreak – usually a combination of the anti-fungal drugs voriconazole (Vfend) and liposomal amphotericin B.

Both drugs have been used for years, but one lesson of the outbreak was how little was actually known about that combination, according to Kauffman.

The outbreak “reinforces the fact that we do not have ideal antifungal agents,” she said. “The experience with giving amphotericin B and voriconazole to these patients has been eye-opening.”

There were “many, many adverse effects, some of which, in the case of AmB, we were prepared for, but many, in the case of voriconazole, were not expected or were much more common than realized previously,” she said.

The optimum duration of therapy – especially given the adverse effects  –  remains an unanswered question. So far, according to Chiller, all treated patients remain on therapy, although many have been discharged from hospital.

How long that will last is anybody’s guess, especially because the effect of treatment on the fungal infections involved is difficult to monitor. If no pathogen can be isolated, is it gone? Or is it still there but just refusing to grow in the lab, or possibly in a dormant state?

“If we had injected people with steroids and a bacteria, this thing would be over,” Chiller said. But fungi, which he called “challenging, interesting, and unpredictable” organisms, have the ability to “hang out and do nothing,” he added.

Then, after a long period of apparent dormancy, they can begin again to cause disease, Chiller said.

And that may be linked to another puzzle of the outbreak – why some people got sick and others did not.

“We understand the route of infection,” Chiller said. “What we don’t understand and have a good handle on is what happened after the injection.”

Infection Control, Appropriate Oversight

While the outbreak is likely to give mycologists interesting research for some time, the bottom line is that contamination of a product that was supposed to be sterile led to hundreds of cases of disease, 39 deaths, and immense suffering.

The FDA has been blamed for not cracking down on the company involved much earlier. The head of the Massachusetts pharmacy board, which is charged with regulating compounding pharmacies in the state, was fired. The company itself is shuttered.

“This disastrous outbreak need not have happened if standard infection control techniques and appropriate oversight had been in place and heeded,” Kauffman said.

Like many others, she believes the federal government should regulate compounding pharmacies, something that is now in the hands of the states.

Under fire from lawmakers, FDA Commissioner Margaret Hamburg, MD, has said her agency’s authority over compounding pharmacies is “limited, unclear, and contested.”

She has suggested a tiered approach under which “traditional” compounding pharmacies – which made up prescriptions for individual patients in limited numbers – would continue to be regulated by states.

But “nontraditional” pharmacies, which make up large quantities of a drug in anticipation of orders, should come under FDA authority, Hamburg has said.

The International Academy of Compounding Pharmacists countered that the FDA already has all the authority it needs. In a statement to a House of Representatives committee, David Miller, RPh, the organization’s executive vice-president, said the problem was that NECC was breaking state laws in a way that gave the FDA clear authority to intervene.

Current law, he said, “allows FDA oversight when a pharmacy is not operating in conformity with governing state laws, or akin to a drug manufacturer.”

Both Miller and others have characterized NECC as a rogue company that was not interesting in complying with the law.

“Unfortunately, NECC showed a blatant disregard for existing rules and regulations,” Miller said.

Inspections of the Framingham plant showed lapses in processes that seemed almost certain to lead eventually to problems, if only because potential contaminants were everywhere.

“We know that sort of contaminant is ubiquitous,” Chiller said. “You need to have a system in place to eliminate them.”

Source: http://www.medpagetoday.com/Neurology/GeneralNeurology/36641?utm

Reckless doctors go unchecked

medmalaa Medical/Health Care Errors Leave a comment

Posted by: Cami McEvers

A database that could identify prolific prescribers and prevent overdose deaths is readily available, but California officials say they lack the resources to take advantage of it.

Drugs

Kamala Harris has a powerful tool for identifying reckless doctors, but she doesn’t use it.

As California’s attorney general, Harris controls a database that tracks prescriptions for painkillers and other commonly abused drugs from doctors’ offices to pharmacy counters and into patients’ hands.

The system, known as CURES, was created so physicians and pharmacists could check to see whether patients were obtaining drugs from multiple providers.

Law enforcement officials and medical regulators could mine the data for a different purpose: To draw a bead on rogue doctors.

But they don’t, and that has allowed corrupt or negligent physicians to prescribe narcotics recklessly for years before authorities learned about their conduct through other means, a Times investigation found.

Prescription drug overdoses have increased sharply over the last decade, fueling a doubling of drug fatalities in the U.S. To help stem the loss of life, the federal Centers for Disease Control and Prevention recommends that states use prescription data to spot signs of irresponsible prescribing, and at least six states do.

California is not one of them.

By monitoring the flow of prescriptions, authorities can get an early jump on illegal or dangerous conduct by a doctor. Among the telltale signs: writing an inordinate number of prescriptions for addictive medications or for combinations of drugs popular among addicts.

Harris’ office keeps CURES off-limits to the public and the news media. But information from a commercial database containing the same kind of data illustrates how valuable CURES could be as an investigative tool.

Private firms purchase prescription data from pharmacies and sell it to drug companies for use in marketing their products. The Times obtained a list from such a database ranking the most prolific prescribers of narcotic painkillers in the Los Angeles area for June 2008.

Of the top 10 doctors on the list, six were eventually convicted of drug dealing or similar crimes or were sanctioned by medical regulators. One of them was a cocaine addict. Some had been prescribing narcotics in high volume for years before authorities caught up with them.

At least 20 of their patients died of overdoses or related causes after taking drugs they prescribed, according to coroners’ records.

Had officials been tracking the doctors’ prescriptions in CURES, some of those deaths might have been prevented.

Harris, a career prosecutor who was elected attorney general in 2010, declined repeated requests to be interviewed for this article.

Nathan Barankin, her chief of staff, said Harris wants to improve CURES so more doctors can use it to identify drug-seeking patients, and to help prosecutors pursue dealers and other drug offenders.

She has not proposed using CURES to detect signs of excessive prescribing.

Barankin said financial constraints limit the attorney general’s options. CURES is “on life support” because of state budget cuts and is barely able to fulfill its primary mission of helping doctors and pharmacists track patients’ use of medications, he said.

Even so, the database, as is, could be used to look for signs of improper prescribing. “It certainly has that capacity, as I understand it,” Barankin said.

He added, however, that if Harris did begin using CURES to monitor doctors, the state Department of Justice lacks the resources to follow up on leads.

“We don’t have the horses or the ability to do that kind of work,” he said.

The Medical Board of California, which licenses and oversees physicians, has appealed to the public to report instances of excessive prescribing, a step it took in response to recent Times articles on overdose deaths.

But the board does not use CURES to identify doctors whose prescribing poses a danger to patients.

“We don’t have the resources,” said executive director Linda K. Whitney.

***

Dr. Tyron Reece was one physician who would have tripped an alarm early on, if officials had been watching his prescriptions in CURES.

The Inglewood family practitioner ranked fourth among prescribers of oxycodone and hydrocodone in the Los Angeles area in June 2008, according to the commercial database. Reece’s customers paid for nearly all those prescriptions in cash, the data show.

The pharmacies that filled Reece’s prescriptions were required by law to report them to CURES.

But Reece was not stopped until 2011, and then only because federal authorities investigating a drug smuggling ring stumbled upon evidence that implicated him. Dozens of prescription vials bearing the doctor’s name had been found in the trash at a suspect’s home.

Confronted by investigators, Reece admitted that he regularly sold prescriptions for cash to patients he had never examined. He pleaded guilty to drug dealing and is awaiting sentencing.

Nathan Kuemmerle, a West Hollywood psychiatrist, was busted in 2010 after narcotics detectives arrested a suspect for selling prescription pills on Craigslist. The suspect identified Kuemmerle as the source of the drugs, court records show.

During their investigation, detectives requested a CURES report on Kuemmerle in 2009 and found that he was the No. 2 prescriber of narcotic painkillers in California and the No. 1 prescriber of the highest-dose form of the stimulant Adderall, according to court records.

Kuemmerle prescribed nearly four times as many of the Adderall pills as the next doctor on the list, the CURES report showed. A medical expert said Kuemmerle wrote an average of 15 prescriptions per day for controlled substances over a four-year period, a “remarkably high” figure, court records show.

Kuemmerle pleaded guilty in 2011 to drug dealing and was sentenced to three years’ probation.

Investigators expressed amazement that Kuemmerle was able to get away with such high-volume prescribing while his prescriptions were being reported to CURES. The failure to use the database to look for signs of improper prescribing closes off a valuable source of leads, they say.

“If a doctor is prescribing in a way that could be considered unreasonable, there is nothing from CURES to say, ‘This might be a problem,’” said Redondo Beach Police Det. Robert Carlborg, who worked on the case. “If there had been, Kuemmerle would have been caught way sooner.”

***

On a warm October afternoon in 2003, Carmen Pack was taking her children to buy Slurpees in the Bay Area suburb of Danville.

Troy, 10, was on his scooter. Alana, 7, was riding her bike.

Heading toward them in a gold Mercedes was Jimena Barreto, a nanny for wealthy families in the area. She had been drinking and popping pills.

The Mercedes careened across two lanes of traffic. Alana was killed instantly. Troy died a few hours later.

Evidence emerged that Barreto was a “doctor shopper” who had obtained prescriptions for painkillers from half a dozen physicians at the same hospital. When the doctors testified at Barreto’s trial, each said they didn’t know about the others’ prescriptions.

That exposed a problem that Bob Pack, the children’s father, set out to remedy.

Pack, a technology entrepreneur, learned that California pharmacists were required to submit detailed data to the state on the controlled substances they dispensed. The information includes the name of the patient and the prescribing physician, as well as the drug and dosage.

The information is stored in the Controlled Substance Utilization Review and Evaluation System — CURES. The system has been in operation in various forms since 1939.

When Pack began studying CURES, doctors or pharmacists who suspected a patient of abusing drugs could call or fax requests to review the patient’s history of filling prescriptions for narcotics. But it could take weeks before they received the desired information.

Pack devised a plan for real-time access to the database. He and some Silicon Valley friends helped design an Internet portal that would allow medical professionals to review a patient’s history of medication use while considering whether to prescribe or dispense new drugs.

State officials embraced the idea.

Pack also pitched a separate component that would automatically alert state officials to doctors with suspicious prescribing patterns. In a recent interview, he called it a “built-in red flag system” that would deliver reports weekly or monthly.

Pack said he discussed the idea with then-Atty. Gen. Jerry Brown in 2007 and met regularly with state officials about the project for a couple of years.

At one meeting, in a demonstration of the database’s potential, staff members presented Brown with a list of the 10 most prolific prescribers of narcotics in the state.

“Jerry Brown and his team were really into that,” Pack recalled.

Brown announced the start of real-time access to CURES at a news conference in September 2009. Pack was at Brown’s side as he touted the “high-tech monitoring system” that would “enable doctors and law enforcement to identify and stop prescription-drug seekers from doctor-shopping and abusing prescription drugs.”

But the idea of using CURES to scrutinize doctors’ prescribing was no longer part of the program. Pack attributed its disappearance to “a combination of apathy and a lack of funding.”

Brown did not respond to requests for comment.

Pack, in an email, said “the idea was always there and still is, but the AG’s office just needs to set it as a priority.”

***

After Brown became governor in 2011, he eliminated the Bureau of Narcotics Enforcement, the unit that operated CURES, as part of his response to the state’s financial crisis.

CURES is now run by a single full-time employee in the attorney general’s office. A private company under contract with the state collects electronic reports on prescriptions from pharmacies and enters them into the database.

The effort is funded with about $400,000 in fees collected annually from the medical board and other professional licensing agencies.

Of more than 212,000 physicians, pharmacists and other professionals eligible for online access to CURES, fewer than 10% have signed up. The attorney general’s office says the database could not handle the demand if every eligible prescriber signed up for online access.

Earlier this month, when one Los Angeles doctor sent an email to the attorney general’s office seeking help accessing CURES to monitor his patients’ drug use, he received an automated response:

“Unfortunately, due to budget restrictions, there is no staff to accept or respond to your communication.”

Medical experts say improving such databases should be a priority because they can play a crucial role in reducing prescription drug deaths.

Prescription monitoring systems are most effective when they focus on doctors rather than on patients, said Len Paulozzi, a public health physician at the Centers for Disease Control and Prevention who specializes in prescription drug abuse.

Paulozzi said CURES could be used for more than generating lists of top prescribers. Officials could, for example, search for instances of patients driving long distances to see a particular doctor, he said. They could also look for physicians who prescribe high dosages of commonly abused drugs.

“Whether you are talking about firemen, policemen or doctors, somebody needs to be looking at what they are doing,” he said in an interview. “I don’t see anything wrong with that.”

Dr. Allen Frances, a professor emeritus of psychiatry at the Duke University School of Medicine and an authority on misuse of prescription drugs, said credit card companies monitor customers’ purchases more closely than most states monitor prescribing of addictive medications.

“This is life and death,” Frances said. “If you can do it for a $100 credit card purchase, why can’t you do it for prescriptions?”

In New York, Massachusetts, Ohio, Kentucky, New Jersey and Wyoming, information from prescription databases that suggests improper prescribing is sent to law enforcement agencies, medical licensing boards or both. West Virginia is developing a program to analyze prescription data to flag problem doctors. South Dakota plans to create a similar program.

Paul Phinney, president of the California Medical Assn., an advocacy and lobbying group for doctors, expressed reservations about this approach, saying that CURES should not become a “big brother” that could make “physicians think twice about prescribing appropriate pain medication.”

But Ronald Wender, former president of the state medical board, said physicians who are prescribing appropriately would have nothing to fear from such scrutiny.

“If you are an oncologist and you are taking care of people in cancer pain, that’s one thing,” said Wender, an anesthesiologist who oversees a large pain-management practice in Los Angeles. “But if you are a general practitioner and writing loads of opioid prescriptions, then something is wrong.”

State officials said it would cost about $2.8million to make CURES more accessible and easier to use, and $1.6 million more per year to keep it running.

State Sen. Mark DeSaulnier (D-Concord), a longtime supporter of CURES whose father struggled with substance abuse, said he would propose legislation in January to finance such an upgrade, and would like to see the system used to track doctors as well as patients.

“People are suffering and dying from overprescribing right now,” DeSaulnier said. “If there are outliers, people need to investigate that and ask questions.”

Source: http://www.latimes.com/news/local/la-me-prescription-cures-20121230,0,1384451.story

Surgical Errors Climb, Bed Sores Decline In State’s Hospitals

medmalaa Medical/Health Care Errors Leave a comment

Posted by: Cami McEvers

Reports of wrong-site surgeries increased 62 percent in the past year in Connecticut hospitals, while the number of patient deaths or disabilities resulting from surgery or falls also rose, a new state report shows.

At the same time, reports of patients suffering from serious pressure ulcers declined, as a number of hospitals made progress in preventing the painful bed sores.

The new Adverse Event Report, compiled by the state Department of Public Health and covering 2011, marks the second year that acute-care hospitals and other medical facilities have been publicly identified by name, as they report errors that caused harm to patients.

The five hospitals with the highest rate of adverse events in 2011, calculated per 100,000 inpatient days, were: Charlotte Hungerford Hospital, in Torrington (49.2); Sharon Hospital (35.4); New Milford Hospital (32.9); Stamford Hospital (19.7); and the Hospital of Central Connecticut, in Southington and New Britain (19.3).

In terms of the sheer volume of events, Yale-New Haven and its affiliated Hospital of St. Raphael accounted for the highest numbers of errors – 21 each – while other large hospitals, such as Hartford and Danbury, also recorded more than 15 adverse events.

Reports of patients suffering from pressure sores declined last year, dropping to 39 – about half the number reported statewide in 2009. Hartford Hospital reported 3 cases, down from 20 in 2009, while Yale-New Haven reported 3, down from 13 in 2009. Eighteen of the state’s 30 acute-care hospitals reported no incidents of pressure ulcers.

Dr. Mary Reich Cooper, vice president and chief quality officer for the Connecticut Hospital Association, said the state’s hospitals are making extensive efforts to identify patients at risk of falls and pressure sores upon admission, and to reduce the likelihood of harm. Noting that the state has made progress in reducing hospital infection rates, she said the association is working with hospitals “to tackle these other issues” by sharing best practices and encouraging a team approach to safety.

In other areas, challenges remain. Reports of patients who had surgery performed on the wrong body part – an error which has been policed closely in recent years – increased from 8 in 2010 to 13 last year. Danbury, Greenwich, Hartford and St. Raphael’s hospitals each reported two such errors.

Before 2010, wrong-site surgeries were relatively rare in Connecticut – there were only two reported statewide in 2009.

Cooper said she believes hospitals have increased their reporting of all adverse events, so that more errors are being publicly disclosed. Although hospitals have adopted “checklists” and other measures to reduce wrong-site surgeries, those measures alone haven’t eradicated human error, she said.

“There’s a lot of focus right now on mindfulness. . . being mindful, instead of just going through the protocol,” she said. There is also an increasing emphasis on “a team approach” to preventing surgical errors, so that no one person is responsible for safety checks.

Reports of patient deaths or serious disability as a result of surgery rose from 16 incidents in 2010 to 21 last year. Five of the incidents were reported at Middlesex Hospital, but officials there said only one of the cases resulted in a death, while the other four were cases in which patients lost large amounts of blood but were not seriously harmed. Eight other hospitals reported one to three cases.

Perforations during open, laparoscopic and endoscopic procedures that resulted in death or serious disability remained high among hospitals, at 49 – up slightly from 2010. Bridgeport and Hartford hospitals each had six such cases.

Despite myriad efforts to reduce falls in hospitals, 96 patients died or were seriously injured from falling in 2011 – up from 91 the year before. Hospitals with the highest numbers of falls included Hungerford and Stamford hospitals, which each had nine cases. Hungerford also had a high rate of pressure ulcers.

Hungerford revamped its wound care program in 2009 to include “a more rigorous prevention and surveillance program” and is aggressively working to reduce falls, according to the hospital’s website.

Because errors are self-reported, state officials caution that some of the variation in rates could be due to underreporting. In July, a report by the U.S. Office of Inspector General found that many adverse events were not reported. In a representative sample of Medicare patients’ cases, 12 percent of the adverse events detected on chart reviews met state reporting requirements, but only 1 percent were actually reported, the study found.

The DPH adverse event report cautions: “Based on these data alone, we cannot derive certain conclusions.  We cannot say whether a high. . . rate reflects highly complete reporting in a facility with good quality of care, or perhaps modestly complete reporting in a facility with poor care, or neither better nor worse quality care.”

The DPH reviews all hospital errors, but does not investigate every case. From Jan. 1, 2012, through Nov. 30, the department investigated about 27 percent of reported adverse events, according to DPH spokesman Bill Gerrish. From 2007 to 2010, about 23 percent of cases were investigated, last year’s report shows.

DPH officials said not every error warrants an investigation, and the agency targets instances where there is noncompliance with regulations or inadequate standards of care. The decision to investigate also is influenced by how often the type of event has been investigated before, and whether DPH is satisfied with a corrective plan that must be submitted by the hospital after an error is reported.

In the new report, DPH notes that in 2010, funding for part-time physician consultants to assist with case reviews was cut, hampering the department’s ability to conduct thorough investigations.

“The Department continues to feel that such specialized medical consultation enhances the comprehensive nature of the investigations, and is exploring alternative funding sources to revitalize this part of the process,” the report says.

In responses included in the report, most hospitals with high error rates described initiatives they were taking to reduce errors. Hartford Hospital touted its efforts to reduce serious falls and hospital-acquired pressure ulcers.

Stamford Hospital, which urged that adverse event reporting be viewed “in the context of the complexity of the patients cared for by the organization,” highlighted its efforts to reduce patient falls through a more detailed fall-risk assessment and targeted interventions for specialized patient populations.

A number of hospitals are participating in a “high reliability” program that seeks to create a culture of safety and make process changes to reduce accidents. At Middlesex Hospital, which reported no serious falls or pressure ulcers in 2011, Dr. Jesse Wagner, vice president for quality and safety, said the hospital had “ramped up” safety efforts in the last two to three years.

Middlesex has programs to identify patients at risk of falls and closely monitor their movements, and checks on patients’ skin conditions as soon as they arrive at the hospital, in order to assess the risks of developing bed sores, he said.  Also, “many of our units are doing hourly rounding” to ensure that patients at risk of falls or sores are assisted, he said.

Danbury and New Milford Hospitals, members of the Western Connecticut Health Network, also said they had stepped-up efforts to reduce preventable harm in 2011 by implementing safety programs. The hospitals have an internal process for detecting “near-miss events,” officials said.

St. Francis Hospital and Medical Center has worked to reduce surgical errors, infections and falls, and has established a “non-punitive culture” for adverse event reporting, its response says.

None of the state’s ambulatory care centers reported more than three adverse incidents in 2011, and most of the reports concerned perforations during laparoscopic or other surgical procedures.

Among the centers, six reported rates higher than 45 incidents per 100,000 visits: The Coastal Digestive Care Center, in New London; Litchfield Hills Surgery Center, in Torrington; Hartford Surgical Center; Waterbury Outpatient Surgical Center; Digestive Disease Associates Endoscopy Suite, in Branford; and Leif O. Nordberg, MD, in Stamford.

To view the state’s adverse event report, click here.

Source: http://c-hit.org/2012/12/25/surgical-errors-climb-bed-sores-decline-in-states-hospitals/

 

 

 

 

 

 

 

Source: http://c-hit.org/2012/12/25/surgical-errors-climb-bed-sores-decline-in-states-hospitals/

Outcome of Kid’s Concussion Hard to Predict

medmalaa Medical News You Can Use Leave a comment

Posted by: Cami McEvers

 

Identifying children most likely to have persistent neurological symptoms following concussion remains a largely hit-or-miss proposition, a systematic literature review suggested.

After reviewing 15 studies that attempted to find predictive factors for persistent concussion symptoms, Roger Zemek, MD, of Children’s Hospital of Eastern Ontario in Ottawa, and colleagues found no consistent pattern in the results.

“Minimal, and at times contradictory evidence exists to associate clinically available factors with eventual development of persistent concussion symptoms in children,” they wrote online in JAMA Pediatrics, the journal formerly known as Archives of Pediatric and Adolescent Medicine.

“Because there is no method to predict which children will experience prolonged symptoms versus which will have a rapid recovery, clinicians must continue to recommend conservative management including both cognitive and physical rest, followed by a stepwise return to activities for all children.”

Zemek and colleagues added that “a multicenter prospective study” is needed to identify factors that could distinguish low-risk from high-risk cases.

“Research to improve care of pediatric concussion depends on early identification of those most in need of intervention,” they argued.

The major problem with the existing studies was what Zemek and colleagues called “excessive heterogeneity” in methods, including patient inclusion and exclusion criteria, definition of concussion, and instruments for measuring post-concussion symptoms.

Such heterogeneity extended beyond the studies they reviewed. The ICD-10 diagnostic system, for example, defines persistent concussion symptoms as those present 1 month after injury, whereas the DSM-IV classification of psychiatric conditions requires symptoms to persist for 3 months.

Zemek and colleagues also pointed to the large array of instruments for measuring persistent symptoms. Ten different assessment tools were used in the 15 studies included in the review.

Starting with 561 published studies on concussion in children, Zemek and colleagues threw out all but 15 for failing to provide data on all of the following clinical factors:

  • Age
  • Medical history including previous concussion
  • Comorbidities including mental health, psychosocial stressors, and coping skills
  • Medication use at presentation
  • Mechanism of injury
  • Symptom presence and severity at initial presentation

 

Enrollment in the 15 studies ranged from 34 to 867; most included control participants who had not suffered head injuries. Controls included healthy siblings as well as children with other types of injuries or illnesses.

Because of the heterogeneity in the 15 studies selected for inclusion, the researchers decided a pooled meta-analysis was impossible.

Nevertheless, some clues to potential predictors could be gleaned from the studies, Zemek and colleagues suggested.

“[Two] larger prospective studies concluded that the risk for developing persistent concussion symptoms was increased in older children with a history of loss of consciousness and either headache or nausea/vomiting,” they found.

“Several smaller studies also noted that initial dizziness may be predictive of prolonged symptoms. While many studies excluded patients with a history of head injury, learning difficulties, or behavioral problems, one study that did not exclude these patients concluded that these pre-morbid conditions also increased risk.”

Zemek and colleagues added that they could not reach “clear conclusions” on factors potentially associated with safe resumption of normal activities such as school and sports.

 

Source: http://www.medpagetoday.com/Neurology/HeadTrauma/36740?utm_content=&utm_medium=email&utm_campaign=DailyHeadlines&utm_source=WC&xid=NL_DHE_2013-01-08&eun=g514381d0r&userid=514381&email=cmcevers@mrglawyers.com&mu_id

Mass. Governor Proposes Compounding Laws

medmalaa Fungal Meningitis Leave a comment

Posted by: Cami McEvers

The Massachusetts Board of Pharmacy would be able to assess fines against compounding pharmacies that violate state law under legislation introduced late Friday by Gov. Deval Patrick (D).

The broad set of reforms, which include requiring special licensure for compounders producing sterile drugs, came in reaction to the multi-state fungal meningitis outbreak linked to more than 600 cases and 40 deaths from steroids made at the troubled New England Compounding Center (NECC).

The legislation is one of a number of proposed reforms at the state and federal level to ensure greater oversight of the safety of drugs produced at compounding pharmacies like Framingham, Mass.-based NECC, which seemed to escape much regulation. State boards of pharmacies oversee compounding pharmacies, while the FDA regulates manufacturers.

NECC produced sterile compounds in the presence of visible mold and bacteria in rooms not kept to standards normal for sterile production, according to inspection reports.

“This legislation makes patient safety paramount and will help fill the gaps in compounding pharmacy monitoring that allowed NECC to operate in the shadows,” Patrick said in a release. “Together these changes can ensure that the tragic events of last fall never happen again.”

Specifically, Patrick’s legislation would:

  • Require a special license for sterile compounding
  • Authorize the state Board of Pharmacy to assess fines against pharmacies that violate state policy, regulations, or laws
  • Establish whistle-blower protections for pharmacists and pharmacy staff
  • Require licensure for out-of-state pharmacies that deliver and dispense medications in Massachusetts
  • Reorganize the composition of the state Board of Pharmacy by including more members who are not practicing pharmacists

 

The last point comes after questions arose in congressional and state investigations about the cozy relationship between NECC and state Board of Pharmacy. Under Patrick’s proposal, the 11-member board would comprise four pharmacists, one nurse, one physician, one pharmacy technician, one quality-improvement expert, and three public members.

Patrick also directed on Friday that the state Department of Public Health increase inspection staff and require inspectors be pharmacists with at least 5 years of clinical experience with expertise in sterile compounding if they work in that area.

Massachusetts has already issued regulations to improve the safety of compounding pharmacies, including requiring sterile compounders in the state to report volume and distribution to the state for the first time. Lawmakers in Washington questioned why the FDA didn’t take action against NECC since it appeared to be operating like a small manufacturer, producing more than 17,000 vials of the tainted methylprednisolone acetate and shipping it to 23 states.

Patrick’s proposals drew praise from a number of state lawmakers who must still pass the bill.

The governor’s release also quotes Rep. Ed Markey (D-Mass.), whose congressional district includes Framingham and the NECC’s headquarters. “I will work closely with Gov. Patrick and anyone in Congress to turn lessons we have learned from this tragedy into law,” Markey said.

The FDA is pushing its own reforms that would need passage by Congress. The agency proposed classifying compounding pharmacies as “traditional” and “nontraditional.”

Traditional compounders, who generally operate under the one-prescription-one-drug paradigm, will still be under the oversight of state boards of pharmacies. Nontraditional compounders would register with the FDA and adhere to other requirements typically mandated for manufacturers.

The clarification is needed, the FDA says, to differentiate what is under the purview of the FDA and what is under purview of the states.

Meanwhile, NECC wrote the Wilmington, Mass.-based cleaning company UniFirst last week asking that it take legal responsibility for the outbreak and “indemnify NECC regarding claims made against NECC.” UniFirst provided once-monthly cleaning services of portions of NECC clean rooms.

UniFirst announced the letter in its quarterly filing with the Securities and Exchange Commission. “Based on its preliminary review of this matter, the Company believes that NECC’s claims are without merit,” the filing read.

Meanwhile, federal investigators continue to pursue criminal charges against the NECC and its management.

 

 

Source: http://www.medpagetoday.com/PublicHealthPolicy/HealthPolicy/36746?utm_content=&utm_medium=email&utm_campaign=DailyHeadlines&utm_source=WC&xid=NL_DHE_2013-01-08&eun=g514381d0r&userid=514381&email=cmcevers@mrglawyers.com&mu_id

1 2 3 4 5 6 7 8 9 10 ... 47 48   Next »